Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer

$ALIM
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ALIM alert in real time by email

ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President and Chief Financial Officer ("CFO"), effective today, January 9, 2023. 

"We are extremely excited to have someone of Russell's caliber join us here at Alimera," said Rick Eiswirth, President and CEO of Alimera. "His extensive tenure in multiple pharma sectors as well as his broad experience in acquisitions and licensing, capital markets, investor relations, and financial operations will help us further achieve our goal of becoming the place to be in retina. We look forward to his engagement and expertise, leveraging his background from a variety of both public and private life sciences companies, in all stages of growth from start-up through commercial stability."

"I am really looking forward to working with the team here at Alimera and with the investment community," said Mr. Skibsted. "I believe ILUVIEN® is a tremendous asset in treating diabetic macular edema that helps patients see better longer, and I am thrilled to help Alimera continue its growth in the retina space".

Mr. Skibsted is a seasoned pharma executive with nearly 30 years of experience in financial management, global business development, capital raises, investor relations, and operations. He has worked with a variety of both public and private life sciences companies at all stages of development. Prior to joining Alimera, he served as Executive Vice President, CFO and Chief Business Officer at Rockwell Medical, a public company providing hemodialysis products.

Previously, Mr. Skibsted served as CFO of BioTime, Inc., a publicly-traded biotechnology company which he joined in 2015, where he also performed the role of CFO at various times for several of BioTime's public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation, a developer of novel, non-invasive tests for the early detection of cancer (November 2015 through November 2017) and Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine with clinical programs in spinal cord injury and oncology immunotherapy (March 2016 through November 2016). Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. He has also acted as a consulting CFO to various life science companies when he was the Managing Director of RSL Ventures.

Earlier in his career, Mr. Skibsted held roles as Portfolio Management Partner and CFO at Asset Management Company, one of the oldest and most respected venture capital firms in Silicon Valley, and Vice President for GE Capital Services Structured Finance Group. Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an M.B.A. from the Stanford Graduate School of Business.

About Alimera Sciences, Inc.

Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

About ILUVIEN

www.ILUVIEN.com

ILUVIEN is a sustained release intravitreal implant injected into the back of the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The 17 European countries include the U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czechia, the Netherlands, and Luxembourg. The non-infectious uveitis affecting the posterior segment indication for ILUVIEN was launched in Germany and the U.K. in late 2019, Belgium in 2021 and Ireland, Spain, and Italy in 2022. ILUVIEN is not approved for treatment of uveitis in the United States.

For investor inquiries:For media inquiries:
Scott Gordon Jules Abraham
for Alimera Sciences for Alimera Sciences
scottg@coreir.comjulesa@coreir.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/1073b7d0-6344-4191-9b60-8780d26ec6b4

https://www.globenewswire.com/NewsRoom/AttachmentNg/37adc5f9-5718-4095-9186-3376db87420b                                           



Primary Logo

Get the next $ALIM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALIM

DatePrice TargetRatingAnalyst
6/25/2024Buy → Neutral
H.C. Wainwright
3/25/2024$10.00Buy
Maxim Group
10/30/2023$8.00Neutral → Buy
Alliance Global Partners
2/25/2022$12.00 → $10.00Buy
HC Wainwright & Co.
8/16/2021$16.00 → $12.00Buy
HC Wainwright & Co.
More analyst ratings

$ALIM
Press Releases

Fastest customizable press release news feed in the world

See more
  • ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

    Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 million on an annualized basis (1)ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin® Gel (Cortrophin

    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

    PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical pr

    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

    PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic

    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALIM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALIM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALIM
SEC Filings

See more

$ALIM
Leadership Updates

Live Leadership Updates

See more
  • Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.  "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Alimera Appoints Maggie A. Pax to Its Board of Directors

    ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Alimera Sciences Appoints Jason Werner as Chief Operating Officer

    ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we

    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALIM
Financials

Live finance-specific insights

See more
  • Alimera Sciences Reports Second Quarter 2024 Results

    Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea

    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

    Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a

    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Alimera Sciences Reports First Quarter 2024 Results

    Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup

    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALIM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more